ascopubs.org

Rationale and design of phase 1 FTIH study of FOXP3 antisense oligonucleotide AZD8701 in patients with selected advanced solid tumors.

A phase 2 study of the MDM2 inhibitor milademetan in patients with TP53-wild type and MDM2-amplified advanced or metastatic solid tumors (MANTRA-2). Design and rationale of a phase 1 dose-escalation ...
Nature

HEALTHY Study Rationale, Design and Methods: Moderating Risk of Type 2 Diabetes in Multi-Ethnic Middle School Students

HEALTHY Study Rationale, Design and Methods: Moderating Risk of Type 2 Diabetes in Multi-Ethnic Middle School Students In this supplement the authors and study group present the rationale and design ...
ascopubs.org

Rationale and Design of the Targeted Agent and Profiling Utilization Registry Study

Intermittent Treatment With MEK Inhibitors in Patients With Oncogenic RAF-Driven Tumors: A Potential Strategy to Manage Toxicity and Maintain Efficacy Case reports and small prospective trials suggest ...
Business Wire

Rationale and Design of CURRENT-OASIS 7 Study Published in American Heart Journal

PARIS AND PRINCETON, N.J.-- (BUSINESS WIRE)--Sanofi-aventis (NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the American Heart Journal published the rationale and design ...